Search Results

There are 2362 results for: content related to: Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage

  1. Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(dl-lactic acid) micelle nanocarriers: Characterization and effects on pharmacokinetics in rat serum and urine

    Journal of Pharmaceutical Sciences

    Volume 101, Issue 10, October 2012, Pages: 3787–3798, Elham A. Mohamed, Yunqi Zhao, Mahasen M. Meshali, Connie M. Remsberg, Thanaa M. Borg, Abdel Monem M. Foda, Jody K. Takemoto, Casey L. Sayre, Stephanie E. Martinez, Neal M. Davies and M. Laird Forrest

    Version of Record online : 17 JUL 2012, DOI: 10.1002/jps.23265

  2. You have free access to this content
    Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells

    International Journal of Cancer

    Volume 126, Issue 3, 1 February 2010, Pages: 743–755, Taofeek K. Owonikoko, Suresh S. Ramalingam, Beatriz Kanterewicz, Trent E. Balius, Chandra P. Belani and Pamela A. Hershberger

    Version of Record online : 20 JUL 2009, DOI: 10.1002/ijc.24759

  3. You have full text access to this Open Access content
    Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors

    Cancer Science

    Volume 100, Issue 9, September 2009, Pages: 1728–1734, Yutaka Fujiwara, Noboru Yamamoto, Yasuhide Yamada, Kazuhiko Yamada, Tetsuya Otsuki, Shinichi Kanazu, Takashi Iwasa, James S. Hardwick and Tomohide Tamura

    Version of Record online : 31 MAY 2009, DOI: 10.1111/j.1349-7006.2009.01237.x

  4. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)

    Pediatric Blood & Cancer

    Volume 60, Issue 3, March 2013, Pages: 390–395, Jodi A. Muscal, Patrick A. Thompson, Terzah M. Horton, Ashish M. Ingle, Charlotte H. Ahern, Renee M. McGovern, Joel M. Reid, Matthew M. Ames, Igor Espinoza-Delgado, Brenda J. Weigel and Susan M. Blaney

    Version of Record online : 9 AUG 2012, DOI: 10.1002/pbc.24271

  5. Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma

    The Journal of Dermatology

    Volume 39, Issue 10, October 2012, Pages: 823–828, Hidefumi WADA, Ryoji TSUBOI, Yukihiko KATO, Makoto SUGAYA, Kensei TOBINAI, Toshihisa HAMADA, Takashi SHIMAMOTO, Kazuo NOGUCHI and Keiji IWATSUKI

    Version of Record online : 16 APR 2012, DOI: 10.1111/j.1346-8138.2012.01554.x

  6. Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma

    British Journal of Haematology

    Volume 171, Issue 1, October 2015, Pages: 74–83, Douglas W. Sborov, Don M. Benson, Nita Williams, Ying Huang, Mindy A. Bowers, Kristina Humphries, Yvonne Efebera, Steven Devine and Craig C. Hofmeister

    Version of Record online : 8 JUN 2015, DOI: 10.1111/bjh.13527

  7. Solubilization of vorinostat by cyclodextrins

    Journal of Clinical Pharmacy and Therapeutics

    Volume 35, Issue 5, October 2010, Pages: 521–526, Y. Y. Cai, C. W. Yap, Z. Wang, P. C. Ho, S. Y. Chan, K. Y. Ng, Z. G. Ge and H. S. Lin

    Version of Record online : 7 JUL 2009, DOI: 10.1111/j.1365-2710.2009.01095.x

  8. Genetic blockade of insulin-like growth factor-1 receptor via recombinant adenovirus in lung cancer can be enhanced by the histone deacetylase inhibitor, vorinostat

    The Journal of Gene Medicine

    Volume 15, Issue 3-4, March-April 2013, Pages: 115–122, Mi-Young Park, Dal Rae Kim, Eun Young Eo, Hyo Jeong Lim, Jong Sun Park, Young-Jae Cho, Ho-Il Yoon, Jae Ho Lee and Choon-Taek Lee

    Version of Record online : 22 APR 2013, DOI: 10.1002/jgm.2699

  9. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT

    Journal of Cellular Physiology

    Volume 226, Issue 9, September 2011, Pages: 2378–2390, Francesca Bruzzese, Alessandra Leone, Monia Rocco, Carmine Carbone, Geny Piro, Michele Caraglia, Elena Di Gennaro and Alfredo Budillon

    Version of Record online : 9 JUN 2011, DOI: 10.1002/jcp.22574

  10. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib

    European Journal of Haematology

    Volume 84, Issue 3, March 2010, Pages: 201–211, Richard A. Campbell, Eric Sanchez, Jeffrey Steinberg, Dror Shalitin, Zhi-Wei Li, Haiming Chen and James R. Berenson

    Version of Record online : 18 NOV 2009, DOI: 10.1111/j.1600-0609.2009.01384.x

  11. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 35, Issue 12, December 2015, Pages: 1173–1188, Salma Afifi, Angela Michael, Mahshid Azimi, Mabel Rodriguez, Nikoletta Lendvai and Ola Landgren

    Version of Record online : 19 DEC 2015, DOI: 10.1002/phar.1671

  12. Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells


    Volume 11, Issue 18, No. 18 September 2011, Pages: 3725–3742, Laura Bianchi, Francesca Bruzzese, Alessandra Leone, Assunta Gagliardi, Michele Puglia, Elena Di Gennaro, Monia Rocco, Anna Gimigliano, Biagio Pucci, Alessandro Armini, Luca Bini and Alfredo Budillon

    Version of Record online : 6 SEP 2011, DOI: 10.1002/pmic.201100092

  13. Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells

    Journal of Cellular Biochemistry

    Volume 112, Issue 10, October 2011, Pages: 3044–3053, Chien-Te Li, Yi-Min Hsiao, Tzu-Chin Wu, Yu-wen Lin, Kun-Tu Yeh and Jiunn-Liang Ko

    Version of Record online : 19 SEP 2011, DOI: 10.1002/jcb.23229

  14. You have free access to this content
    The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy

    Journal of Orthopaedic Research

    Volume 29, Issue 4, April 2011, Pages: 623–632, Erik R. Sampson, Vinit Amin, Edward M. Schwarz, Regis J. O'Keefe and Randy N. Rosier

    Version of Record online : 18 OCT 2010, DOI: 10.1002/jor.21274

  15. You have free access to this content
    A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia

    British Journal of Haematology

    Volume 150, Issue 1, July 2010, Pages: 72–82, Tapan M. Kadia, Hui Yang, Alessandra Ferrajoli, Sirisha Maddipotti, Claudia Schroeder, Timothy L. Madden, Julianne L. Holleran, Merrill J. Egorin, Farhad Ravandi, Deborah A. Thomas, Willie Newsome, Blanca Sanchez-Gonzalez, James A. Zwiebel, Igor Espinoza-Delgado, Hagop M. Kantarjian and Guillermo Garcia-Manero

    Version of Record online : 29 APR 2010, DOI: 10.1111/j.1365-2141.2010.08211.x

  16. You have free access to this content
    A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

    British Journal of Haematology

    Volume 167, Issue 2, October 2014, Pages: 185–193, Mark Kirschbaum, Ivana Gojo, Stuart L. Goldberg, Christopher Bredeson, Lisa A. Kujawski, Allen Yang, Peter Marks, Paul Frankel, Xing Sun, Alessandra Tosolini, Joseph E. Eid, Gregory M. Lubiniecki and Jean-Pierre Issa

    Version of Record online : 8 JUL 2014, DOI: 10.1111/bjh.13016

  17. Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine

    Biomedical Chromatography

    P.S. Suresh, V.C. Devaraj, Nuggehally R. Srinivas and Ramesh Mullangi

    Version of Record online : 13 SEP 2016, DOI: 10.1002/bmc.3807

  18. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

    British Journal of Haematology

    Volume 171, Issue 1, October 2015, Pages: 52–59, David H. Vesole, Elizabeth Bilotti, Joshua R. Richter, Ann McNeill, Laura McBride, Laura Raucci, Palka Anand, Urszula Bednarz, Kristin Ivanovski, Judith Smith, Veena Batra, Adolfo Aleman, Taliah Sims, Laura Guerrero, Anthony Mato and David S. Siegel

    Version of Record online : 27 MAY 2015, DOI: 10.1111/bjh.13517

  19. You have free access to this content
    The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells

    British Journal of Pharmacology

    Volume 162, Issue 7, April 2011, Pages: 1590–1602, CE Tiffon, JE Adams, L van der Fits, S Wen, PA Townsend, A Ganesan, E Hodges, MH Vermeer and G Packham

    Version of Record online : 4 MAR 2011, DOI: 10.1111/j.1476-5381.2010.01188.x

  20. You have free access to this content
    A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma

    British Journal of Haematology

    Volume 161, Issue 2, April 2013, Pages: 183–191, Lihua E. Budde, Michelle M. Zhang, Andrei R. Shustov, John M. Pagel, Ted A. Gooley, George R. Oliveira, Tara L. Chen, Nancy L. Knudsen, Jennifer E. Roden, Britt E. Kammerer, Shani L. Frayo, Thomas A. Warr, Thomas E. Boyd, Oliver W. Press and Ajay K. Gopal

    Version of Record online : 29 JAN 2013, DOI: 10.1111/bjh.12230